CROSSJECT: management transactions · France · AMF

About CROSSJECT

CROSSJECT is a French specialty pharmaceutical company listed on Euronext Growth Paris under ticker ALCJ and ISIN FR0011716265. Founded in 2001 by Patrick Alexandre and headquartered in Dijon, the company has built its strategy around a clear mission: to develop easy-to-use, fast and reliable self-administration solutions for emergency medicines. Its core asset is ZENEO®, a proprietary needle-free, pre-filled, single-use auto-injector designed to enable intramuscular delivery by untrained patients, caregivers or healthcare professionals in critical situations. CROSSJECT’s business model is that of an innovation-driven biopharmaceutical company focused on niche emergency-care markets. The lead program is ZEPIZURE®, an emergency treatment for epileptic seizures, alongside other development priorities such as anaphylactic shock and acute adrenal insufficiency. The company also states that it is working on additional products for other life-threatening conditions where immediate drug delivery is essential. This positioning gives CROSSJECT exposure to unmet medical needs rather than broad primary-care competition, which can create strategic differentiation if regulatory and commercial milestones are achieved. A major part of the investment case lies in regulatory and industrial progress. CROSSJECT says it is in advanced regulatory development for ZEPIZURE® and has secured a $60 million contract with BARDA, the U.S. Biomedical Advanced Research and Development Authority. The company notes that the total value of the agreement could reach $155 million if all options are exercised. This relationship is important because it supports development, regulatory work and the potential initial delivery into the U.S. Strategic National Stockpile, making the U.S. market a key growth platform. Geographically, CROSSJECT remains anchored in France while expanding its North American footprint, particularly in the United States. The company highlights a dedicated U.S. presence and commercialization ambitions starting with ZEPIZURE®. Its share has been listed since February 28, 2014, and the stock is eligible for PEA and PEA-PME, which is relevant for French retail investors. Notable corporate facts include the company’s long R&D history, the positioning of ZENEO® as a platform protected until 2038 according to company communications, and the publication in March 2026 of full-year 2025 results confirming a strengthening operational, industrial and financial trajectory. Overall, CROSSJECT remains a high-risk, high-upside healthcare small cap, whose valuation depends heavily on execution, regulatory approvals and eventual monetization of its proprietary emergency-care platform.